Takeda India announced the launch of vedolizumab (Kynteles) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and Crohn’s Disease (CD).
UC and CD are chronic idiopathic inflammatory bowel diseases (IBDs) that can be debilitating and sometimes lead to life-threatening complications and require life-long disease management.
Vedolizumab is a gut-selective biologic and is approved as an intravenous (IV) formulation. It is a humanised monoclonal antibody designed to specifically antagonise the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 integrin to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1).
MAdCAM-1 is preferentially expressed on blood vessels and lymph nodes of the gastrointestinal tract. The alpha4beta7 integrin is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in UC and CD. By inhibiting alpha4beta7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.
“India has the highest burden of IBD in Asia and one of the highest in the world as a result of rapid urbanisation, changes in diet and lifestyles. Vedolizumab with its novel mechanism of action, selectively reduces intestinal inflammation that allows long-lasting remission and provides a safe and effective treatment option for patients with UC and CD,” said Dr Sandeep Arora, Medical Affairs Head, Takeda India.
There are currently over 1.5 million IBD patients in India. Vedolizumab IV is approved for the management of patients with moderately to severely active UC and CD, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα)-antagonist.